Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

High mortality among patients with cancer and COVID-19 infection: the experience of a Brazilian cancer center.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Instituto de Ensino e Pesquisa Albert Einstein Country of Publication: Brazil NLM ID: 101281800 Publication Model: eCollection Cited Medium: Internet ISSN: 2317-6385 (Electronic) Linking ISSN: 16794508 NLM ISO Abbreviation: Einstein (Sao Paulo) Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: São Paulo, SP : Instituto de Ensino e Pesquisa Albert Einstein
    • الموضوع:
      COVID-19* ; Neoplasms*; COVID-19 Testing ; Comorbidity ; Female ; Hospitalization ; Humans ; Male ; Respiration, Artificial ; Retrospective Studies ; Risk Factors ; SARS-CoV-2
    • نبذة مختصرة :
      Objective: To evaluate the severity of COVID-19 in cancer patients to describe clinical and epidemiological factors associated with poor outcomes (mortality and need of intensive care unit admission or mechanical ventilation).
      Methods: Retrospective data from patients with cancer and laboratory diagnosis of COVID-19, obtained between March 16 and May 29, 2020, were retrieved out of a cancer center database. Data analyzed included patient history, age, sex, comorbidities, types of cancer and anticancer therapy.
      Results: This sample comprised 105 patients aged 18-92 years, 80.9% of whom were females. Dyspnea was the most prevalent initial symptom (30.4%) among patients who died (p<0.0001). Overall, 57.1% of patients had metastatic disease and 60% had poor performance status (Eastern Cooperative Oncologic Group ≥2) at the time of COVID-19 diagnosis. The overall mortality rate was 40.95%. Mortality rates were higher in male patients and those with poor performance status (p<0.0001).
      Conclusion: This cohort is one of the largest Brazilian studies describing clinical and epidemiological features of patients with cancer and concurrent COVID-19. Findings of this study emphasize the vulnerability of cancer patients in the current pandemic, and indicate high mortality from COVID-19 among male cancer patients and cancer patients with poor performance status. This analysis may assist the selection of patients who may benefit from strict isolation and eventual discontinuation of anticancer therapy to reduce exposure to infection.
    • References:
      Clin Microbiol Infect. 2020 Jun;26(6):767-772. (PMID: 32304745)
      J Travel Med. 2020 May 18;27(3):. (PMID: 32211799)
      JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
      J Clin Virol. 2020 Jun;127:104364. (PMID: 32311650)
      Nat Med. 2020 May;26(5):665-671. (PMID: 32405058)
      N Engl J Med. 2020 May 28;382(22):2163-2164. (PMID: 32283004)
      Oncologist. 2020 Jun;25(6):e936-e945. (PMID: 32243668)
      Ann Oncol. 2020 Jul;31(7):894-901. (PMID: 32224151)
      PLoS Negl Trop Dis. 2020 May 7;14(5):e0008265. (PMID: 32379757)
      Lancet Haematol. 2020 Jun;7(6):e432-e435. (PMID: 32339482)
      Lancet. 2020 Feb 15;395(10223):470-473. (PMID: 31986257)
      Mil Med Res. 2020 Mar 13;7(1):11. (PMID: 32169119)
      J Infect. 2020 Aug;81(2):318-356. (PMID: 32298677)
      Eur J Cancer. 2020 Nov;139:43-50. (PMID: 32971510)
      Eur Radiol. 2020 Aug;30(8):4417-4426. (PMID: 32279115)
      Int J Qual Health Care. 2021 Mar 5;33(1):. (PMID: 32472140)
      Clin Infect Dis. 2020 Jul 28;71(15):769-777. (PMID: 32176772)
      Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
      Pol Arch Intern Med. 2020 May 29;130(5):390-399. (PMID: 32329978)
      Lancet. 2020 Jun 20;395(10241):1907-1918. (PMID: 32473681)
      Lancet Infect Dis. 2020 May;20(5):547-548. (PMID: 32311323)
      Lancet Oncol. 2020 May;21(5):619-621. (PMID: 32220659)
      Braz J Infect Dis. 2020 Mar - Apr;24(2):93-95. (PMID: 32335078)
      JAMA Oncol. 2020 Jul 1;6(7):1108-1110. (PMID: 32211820)
      Oncoimmunology. 2020 May 5;9(1):1760686. (PMID: 32923119)
      ESMO Open. 2017 Oct 12;2(4):e000105. (PMID: 29259818)
      Nat Med. 2020 Jul;26(7):1146. (PMID: 32494062)
      BMJ. 2020 May 22;369:m1966. (PMID: 32444366)
      CMAJ. 2020 Mar 9;192(10):E264-E265. (PMID: 32152059)
      PLoS One. 2020 Oct 26;15(10):e0241261. (PMID: 33104715)
      PLoS One. 2020 Aug 27;15(8):e0238281. (PMID: 32853230)
      Nat Hum Behav. 2020 Aug;4(8):856-865. (PMID: 32737472)
      Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541)
      JAMA. 2020 Jun 2;323(21):2195-2198. (PMID: 32329797)
      Ann Oncol. 2020 Aug;31(8):1088-1089. (PMID: 32330541)
      Epidemiol Infect. 2020 Sep 30;148:e238. (PMID: 32993821)
      J Clin Virol. 2020 Jun;127:104378. (PMID: 32353762)
      J Med Virol. 2020 Jul;92(7):797-806. (PMID: 32198776)
    • الموضوع:
      Date Created: 20211110 Date Completed: 20211111 Latest Revision: 20211113
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC8555874
    • الرقم المعرف:
      10.31744/einstein_journal/2021AO6254
    • الرقم المعرف:
      34755809